Cytokinetics to Participate in September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in September: Citi 2026 BioPharma Back to School Conference: Fireside chat on Wednesday, September 9, 2026 at 3:00 PM Eastern Time in New York, NY.

GlobeNewsWire • Sep 2, 2026

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.

Zacks Investment Research • Sep 2, 2026

Cytokinetics Investors Weigh Safety Data From Pivotal Trial

Cytokinetics Incorporated (NASDAQ:CYTK) on Friday shared primary results from the ACACIA-HCM Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).

Benzinga • Aug 31, 2026

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026

Additional Results from ACACIA-HCM Demonstrate Improvements in  Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM New Analysis of MAPLE-HCM Finds Aficamten Outperformed Metoprolol Across Pre-Trial Treatment Groups in Patients with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Aug. 29, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from ACACIA-HCM (Assessment Comparing A ficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) and MAPLE-HCM ( M etoprolol vs A ficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) were presented in a Late Breaking Clinical Session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany and simultaneously published in Circulation and the Journal of the American College of Cardiology: Heart Failure, respectively.

GlobeNewsWire • Aug 29, 2026

Cytokinetics eyes expanded use of heart drug after promising late-stage data

Cytokinetics said on Friday detailed late-stage data showed its drug, aficamten, significantly improved symptoms and exercise capacity in patients with a genetic heart ​condition that currently has no approved treatments.

Reuters • Aug 28, 2026

Cytokinetics Scores A First-Ever In Its Rivalry Against Bristol Myers

Cytokinetics scored the first-ever win for a Phase 3 study in non-obstructive hypertrophic cardiomyopathy on Friday.

Investors Business Daily • Aug 28, 2026

Cytokinetics' Aficamten Hits Dual Phase III Endpoints in Non-Obstructive HCM

Cytokinetics NASDAQ: CYTK presented primary results from its Phase III ACACIA-HCM trial evaluating aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, or nHCM, reporting that the study met its dual primary endpoints for patient-reported health status and exercise capacity.

MarketBeat • Aug 28, 2026

Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Aficamten in Nonobstructive HCM Transcript

Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Aficamten in Nonobstructive HCM Transcript

Seeking Alpha • Aug 28, 2026

Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine

ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM Supplemental New Drug Application to be Submitted to FDA in Fourth Quarter Company to Host Investor Event and Webcast Today at 2:00 PM Central European Summer Time (8:00 AM Eastern Time) SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the primary results from ACACIA-HCM (Assessment Comparing A ficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, and simultaneously published in  The New England Journal of Medicine .1 ACACIA-HCM met both dual primary endpoints, demonstrating statistically significant improvements from baseline to Week 36 compared to placebo in both Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and maximal exercise performance (pVO2).

GlobeNewsWire • Aug 28, 2026

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700

The transaction involved the disposal of 7,500 shares. The disposition resulted in a 2% reduction in the insider's total equity holdings.

The Motley Fool • Aug 22, 2026